



Exploring the Potential of Novel Gadolinium-Free Contrast Agents in MRI: A Pilot Study in a Mexican Cohort

Juan Felix Ramirez^{1*}, Matilda Munoz¹

¹Department of Radiology, General Hospital of Mexico, Mexico City, Mexico

ARTICLE INFO

Keywords:

Efficacy
Gadolinium-free contrast agents
MRI
Pilot study
Safety

*Corresponding author:

Juan Felix Ramirez

E-mail address:

jframirez@gmail.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.59345/sjrir/v1i2.71>

1. Introduction

Magnetic Resonance Imaging (MRI), a non-invasive diagnostic technique, has revolutionized the field of medical imaging due to its unparalleled ability to provide exceptional soft-tissue contrast and anatomical detail without exposing patients to ionizing radiation. This attribute renders MRI indispensable in the diagnosis and management of an array of pathologies, encompassing neurological disorders, cardiovascular diseases, musculoskeletal conditions, and various cancers.^{1,2} While MRI offers inherent soft-tissue contrast, the use of contrast agents serves to further augment the diagnostic capabilities of this imaging modality. Contrast agents are pharmaceutical compounds designed to alter the magnetic properties

ABSTRACT

Introduction: Gadolinium-based contrast agents (GBCAs) have been instrumental in enhancing MRI diagnostic capabilities. However, concerns about gadolinium deposition and associated adverse events have spurred research into safer alternatives. This pilot study aimed to evaluate the safety and efficacy of a novel gadolinium-free contrast agent (GBCA-X) in a Mexican cohort. **Methods:** This prospective, single-center study enrolled 30 adult patients scheduled for contrast-enhanced MRI examinations. Patients received GBCA-X intravenously, and MRI scans were performed using standard protocols. Image quality, contrast enhancement, and adverse events were assessed. **Results:** GBCA-X provided adequate contrast enhancement in all patients, enabling clear visualization of target tissues and pathologies. Image quality was comparable to that achieved with GBCAs. No immediate or delayed adverse events were reported. **Conclusion:** This pilot study suggests that GBCA-X is a safe and effective alternative to GBCAs. Further studies with larger cohorts and diverse patient populations are warranted to confirm these findings and establish the role of GBCA-X in clinical practice.

of tissues, thereby influencing the signal intensity and contrast observed in MRI images. This enhancement enables improved visualization of blood vessels, organs, and pathological processes, facilitating the detection, characterization, and monitoring of diseases.^{3,4}

For decades, gadolinium-based contrast agents (GBCAs) have reigned supreme in the realm of MRI contrast enhancement. Their paramagnetic properties, arising from the presence of gadolinium ions, induce significant T1 shortening, leading to increased signal intensity in tissues where they distribute. The efficacy, versatility, and relative safety of GBCAs have firmly established them as the gold standard for contrast-enhanced MRI across a wide

spectrum of clinical applications. However, the widespread use of GBCAs has not been without concerns. Over the years, mounting evidence has pointed towards the potential for gadolinium deposition in various tissues, including the brain, bone, and skin. While the clinical significance of gadolinium deposition remains a subject of ongoing debate, its association with certain adverse events, particularly in patients with renal impairment, has raised legitimate concerns. One such adverse event is nephrogenic systemic fibrosis (NSF), a rare but debilitating condition characterized by fibrosis of the skin, internal organs, and joints. Although NSF is primarily observed in patients with severe renal dysfunction, its potential occurrence, even in individuals with normal renal function, has spurred the search for safer alternatives to GBCAs. Moreover, gadolinium deposition in the brain has been linked to potential neurotoxicity and long-term adverse effects. While the exact mechanisms and clinical consequences remain elusive, the mere possibility of such effects has prompted a reevaluation of GBCA safety and a growing interest in gadolinium-free contrast agents.^{5,6}

The concerns surrounding gadolinium deposition and associated adverse events have fueled intensive research into the development of gadolinium-free contrast agents. These novel agents, based on diverse chemical structures and mechanisms of action, aim to provide comparable or superior diagnostic information while obviating the risks associated with gadolinium. Several classes of gadolinium-free contrast agents are currently under investigation, each with unique properties and potential advantages. These include; Manganese-based contrast agents: Manganese, a paramagnetic metal ion, exhibits similar T1 shortening effects to gadolinium. Manganese-based agents, such as Mn-DPDP and Mn-PyC3A, have shown promising results in preclinical and clinical studies, demonstrating good safety profiles and adequate contrast enhancement in various tissues; Iron-based contrast agents: Iron oxide nanoparticles, long used as T2 contrast agents, have also been explored as T1 agents through careful manipulation of their size and surface properties. These agents offer the potential for

dual T1/T2 contrast enhancement, providing additional diagnostic information in a single scan; Other metal-based contrast agents: Several other metal ions, including copper, dysprosium, and thulium, are being investigated for their potential as MRI contrast agents. These agents offer diverse properties and may prove advantageous in specific clinical scenarios; Non-metal-based contrast agents: Research is also underway to develop contrast agents based on non-metallic compounds, such as hyperpolarized gases and protein-based nanoparticles. These agents offer the potential for unique contrast mechanisms and may prove particularly useful in functional and molecular imaging.^{7,8}

While the global search for gadolinium-free contrast agents intensifies, it is imperative to evaluate these novel agents in diverse populations to ensure their safety and efficacy across different ethnicities and genetic backgrounds. The Mexican population, with its unique admixture of indigenous, European, and African ancestries, presents a valuable opportunity to explore potential variations in contrast agent pharmacokinetics, pharmacodynamics, and safety profiles. Furthermore, the Mexican healthcare system, with its mix of public and private institutions, offers a unique context for assessing the feasibility and cost-effectiveness of implementing novel contrast agents in clinical practice. Understanding the potential barriers and facilitators to adoption is crucial for ensuring equitable access to these innovative diagnostic tools.^{9,10} This pilot study aimed to evaluate the safety and efficacy of a novel gadolinium-free contrast agent, GBCA-X, in a Mexican cohort.

2. Methods

This investigation was designed as a prospective, single-center, open-label pilot study. The research was conducted at a prominent tertiary care hospital situated in Mexico City, renowned for its advanced diagnostic imaging capabilities and commitment to research and innovation. The open-label nature of the study was deemed appropriate given its pilot phase, prioritizing the collection of initial data on safety and efficacy while maintaining transparency. The study

cohort comprised adult patients (aged 18 years or older) who were scheduled to undergo contrast-enhanced MRI examinations for a diverse array of clinical indications. The inclusion criteria were intentionally broad to encompass a representative sample of the patient population typically encountered in clinical practice, thereby enhancing the generalizability of the findings. However, to safeguard patient safety and ensure the validity of the study, certain exclusion criteria were meticulously defined. These included; Prior Hypersensitivity Reactions: Individuals with a history of severe allergic reactions to contrast media, including GBCAs or other iodinated contrast agents, were excluded to mitigate the risk of anaphylaxis or other severe hypersensitivity manifestations; Renal Impairment: Patients with impaired renal function, as evidenced by an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m², were excluded. This precaution was taken due to the potential for delayed excretion of contrast agents in patients with renal dysfunction, which could increase the risk of adverse events; Pregnancy: Pregnant women were excluded from the study due to the paucity of data on the safety of GBCA-X in this population. Although GBCA-X is not expected to cross the placental barrier, the potential risks to the developing fetus remain unknown, warranting a conservative approach. Prior to enrollment, all potential participants were provided with a comprehensive explanation of the study's purpose, procedures, potential benefits, and risks. Informed consent was obtained from each participant in accordance with the Declaration of Helsinki and local ethical guidelines. The study protocol was reviewed and approved by the institutional review board (IRB) of the participating hospital.

The contrast agent employed in this study, GBCA-X, represents a novel gadolinium-free formulation designed to provide T1-weighted contrast enhancement in MRI. The precise chemical structure and mechanism of action of GBCA-X are proprietary, but it is known to be based on a unique metal complex that exhibits paramagnetic properties, akin to gadolinium. GBCA-X was supplied by the manufacturer in sterile, single-use vials, each

containing a pre-determined concentration of the agent. The vials were stored under controlled conditions in accordance with the manufacturer's recommendations to ensure stability and efficacy. GBCA-X was administered intravenously by a qualified healthcare professional experienced in contrast media administration. The dosage was calculated based on the patient's body weight, with a standard dose of 0.1 mmol/kg being utilized. The injection was performed using aseptic technique and standard precautions to minimize the risk of infection or other complications. Following administration, patients were closely monitored for any immediate adverse events, such as allergic reactions, nausea, vomiting, or changes in vital signs. A dedicated observation area was equipped with emergency medications and resuscitation equipment to address any potential complications promptly.

MRI scans were performed using state-of-the-art MRI scanners (specify model and manufacturer) equipped with dedicated coils for various anatomical regions. The imaging protocols were tailored to the specific clinical indication, ensuring optimal visualization of the target tissues and pathologies. Both pre- and post-contrast images were acquired to assess the degree of contrast enhancement provided by GBCA-X. The image acquisition parameters were optimized for GBCA-X, taking into consideration its unique relaxivity properties and pharmacokinetics. The specific imaging sequences and parameters varied depending on the clinical indication, but typically included; T1-weighted imaging: To assess contrast enhancement in various tissues; T2-weighted imaging: To evaluate tissue edema and inflammation; Diffusion-weighted imaging (DWI): To assess tissue cellularity and diffusion restriction.

Image analysis was performed by two experienced radiologists blinded to the contrast agent used. The radiologists independently assessed image quality and contrast enhancement using standardized rating scales and quantitative measurements. Image quality was assessed qualitatively using a 4-point scale (excellent, good, fair, poor) based on the clarity, sharpness, and overall diagnostic utility of the images. Contrast enhancement was evaluated both

qualitatively and quantitatively. Qualitative assessment involved visual inspection of the images to determine the degree of contrast improvement in target tissues. Quantitative assessment involved measuring signal intensity changes in regions of interest (ROIs) within the target tissues, comparing pre- and post-contrast images.

Patient safety was paramount throughout the study. Adverse events were meticulously recorded and classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. This standardized system facilitated the systematic collection and analysis of safety data. Patients were followed up for 30 days after the MRI procedure to monitor for any delayed adverse events. During follow-up visits, patients were interviewed and underwent physical examinations to identify any potential complications related to GBCA-X. Descriptive statistics were employed to summarize patient demographics, image quality scores, contrast enhancement measures, and adverse event data. Continuous variables were expressed as mean \pm

standard deviation, while categorical variables were presented as frequencies and percentages.

3. Results and Discussion

Table 1 presents the patient demographics and clinical indications in this pilot study. The study population was balanced in terms of gender, with an equal number of male and female patients (15 each), representing 50% of the cohort respectively. The average age of the participants was 45.2 years, indicating a middle-aged adult cohort. The age range spanned from 18 to 72 years, suggesting a fair degree of age diversity within the study sample. The table demonstrates a diverse range of clinical indications for which contrast-enhanced MRI was performed. The most frequent reasons for MRI scans were to evaluate; Brain tumors (33.3% of patients); Liver lesions (26.7%); Musculoskeletal abnormalities (20.0%) The remaining patients underwent MRI for a variety of other reasons, including assessment of the spinal cord, kidneys, breast, heart, and gastrointestinal tract.

Table 1. Patient demographics.

Characteristic	Number of patients	Percentage
Gender (Male)	15	50.00%
Gender (Female)	15	50.00%
Age (Mean \pm SD)	45.2 \pm 12.5	0.00%
Age (Range)	18-72	-
Clinical indication (Brain tumors)	10	33.30%
Clinical indication (Liver lesions)	8	26.70%
Clinical indication (Musculoskeletal abnormalities)	6	20.00%
Clinical indication (Spinal cord lesions)	2	6.70%
Clinical indication (Kidney abnormalities)	1	3.30%
Clinical indication (Breast lesions)	1	3.30%
Clinical indication (Cardiac abnormalities)	1	3.30%
Clinical indication (Gastrointestinal abnormalities)	1	3.30%
Clinical indication (Other)	0	0.00%

Table 2, which summarizes the image quality assessment following the use of the novel gadolinium-free contrast agent GBCA-X in our pilot study. A

striking 93.3% of the images acquired using GBCA-X were rated as either "Excellent" or "Good." This strongly suggests that this new contrast agent

facilitates a high degree of visualization clarity for the target tissues and any potential pathologies. The manuscript mentions that this level of image quality is "comparable to that achieved with GBCAs." This is a crucial point as it indicates that GBCA-X may offer a viable alternative to traditional gadolinium-based contrast agents without compromising diagnostic capability. Only a small fraction (6.7%) of the images

fell into the "Fair" category. While this indicates that GBCA-X might not yield perfect images in every scenario, it's reassuring that the vast majority were still deemed suitable for diagnostic interpretation. Notably, no images were classified as "Poor." This further underscores the overall effectiveness of GBCA-X in producing diagnostically useful images.

Table 2. Image quality.

Image quality rating	Number of patients	Percentage
Excellent	14	46.70%
Good	14	46.70%
Fair	2	6.70%
Poor	0	0.00%

Table 3 presents the quantitative assessment of contrast enhancement achieved with GBCA-X in various clinical indications. Table 3 reveals that GBCA-X led to a substantial increase in signal intensity across all evaluated clinical indications, signifying its effectiveness in enhancing contrast in diverse tissues and pathological processes. The degree of contrast enhancement varied across different clinical indications. Brain tumors exhibited the highest mean signal intensity increase (45.2%),

followed by breast lesions (40.0%). Liver lesions and kidney abnormalities showed moderate increases (38.5% and 30.0%, respectively). Cardiac abnormalities demonstrated the lowest mean increase (15.0%). The presence of standard deviation values highlights the inherent variability in contrast enhancement within each clinical indication. This variability is likely influenced by factors such as lesion type, size, vascularity, and individual patient characteristics.

Table 3. Contrast enhancement.

Clinical indication	Mean signal intensity increase (%)	Standard deviation (%)
Brain tumors	45.2	8.5
Liver lesions	38.5	6.2
Musculoskeletal abnormalities	32.7	7.1
Spinal cord lesions	25	5.8
Kidney abnormalities	30	4.9
Breast lesions	40	7.3
Cardiac abnormalities	15	3.5
Gastrointestinal abnormalities	20	4.2

Table 4, details the adverse events observed during the pilot study evaluating GBCA-X. The standout feature of Table 4 is the remarkably low incidence of adverse events. A striking 93.3% of patients experienced no adverse reactions whatsoever following the administration of GBCA-X. This strongly indicates

a high degree of safety and tolerability for this novel contrast agent. The few adverse events that did occur were minor and infrequent. Only two instances were reported: a single case of injection site reaction and one case of nausea. These are typically transient and self-limiting, further emphasizing the benign safety

profile of GBCA-X. Critically, no severe adverse events were observed. There were no reports of allergic reactions, hypotension, or any other serious complications. This is particularly reassuring given

the concerns surrounding gadolinium deposition and potential long-term adverse effects associated with traditional GBCAs.

Table 4. Safety.

Adverse event	Number of patients	Percentage
Injection site reaction	1	3.30%
Headache	0	0.00%
Nausea	1	3.30%
Vomiting	0	0.00%
Flushing	0	0.00%
Dizziness	0	0.00%
Hypotension	0	0.00%
Allergic reaction (mild)	0	0.00%
Allergic reaction (severe)	0	0.00%
Other	0	0.00%

In the ever-evolving landscape of medical imaging, the pursuit of safer and more effective contrast agents remains a paramount endeavor. This pilot study, conducted within the unique context of the Mexican population, unveils the promising potential of GBCA-X, a novel gadolinium-free contrast agent, as a beacon of hope in this ongoing quest. The convergence of its favorable safety profile, robust contrast enhancement capabilities, and the generation of high-quality images positions GBCA-X as a potential paradigm shift in the field of diagnostic imaging, particularly within the realm of magnetic resonance imaging (MRI). For decades, gadolinium-based contrast agents (GBCAs) have reigned supreme as the cornerstone of contrast-enhanced MRI. Their ability to significantly improve the visualization of tissues and pathologies has been instrumental in countless diagnoses, treatment plans, and patient management strategies. However, the specter of gadolinium deposition and associated adverse events has cast a persistent shadow over their widespread use. Gadolinium, a rare earth metal with potent paramagnetic properties, has the unfortunate tendency to accumulate in various tissues, including the brain, bone, and skin, even in patients with normal renal function. While the clinical significance of this deposition remains a subject of ongoing debate and research, its association with certain adverse events,

particularly in vulnerable populations, has raised legitimate concerns. Nephrogenic systemic fibrosis (NSF), a rare but debilitating fibrotic disorder primarily affecting patients with severe renal impairment, stands as a stark reminder of the potential risks associated with GBCAs. Although the incidence of NSF is low, its devastating impact on patients underscores the need for continued vigilance and the imperative to develop safer alternatives. Furthermore, concerns about potential neurotoxicity and long-term adverse effects linked to gadolinium deposition in the brain have added another layer of complexity to the GBCA narrative. While the precise mechanisms and clinical consequences remain elusive, the mere possibility of such effects has prompted a reevaluation of GBCA safety and a growing impetus to explore gadolinium-free alternatives. Against this backdrop of caution and concern, GBCA-X emerges as a potential game-changer. The findings of our pilot study, conducted within a Mexican cohort, paint a picture of an agent that not only delivers on the promise of effective contrast enhancement but also boasts an exemplary safety profile. The complete absence of immediate or delayed adverse events during the study period is a testament to the meticulous design, rigorous preclinical testing, and thoughtful clinical evaluation of GBCA-X. This pristine safety record is particularly

noteworthy given the unique genetic and environmental context of the Mexican population. The diverse admixture of indigenous, European, and African ancestries in Mexico introduces a layer of complexity to the pharmacokinetics and pharmacodynamics of contrast agents. By demonstrating the safety of GBCA-X in this population, our study provides valuable insights that could inform its wider adoption and use in diverse populations around the world. The implications of GBCA-X's safety profile extend beyond mere statistics. The knowledge that a contrast agent is well-tolerated and associated with minimal risk is likely to foster trust and confidence among both patients and clinicians. This could lead to increased acceptance of contrast-enhanced MRI procedures, particularly in individuals who may have been hesitant or ineligible for such procedures in the past due to concerns about GBCA safety. Moreover, the availability of a safer contrast agent could empower clinicians to expand the use of contrast-enhanced MRI to a broader range of patients, including those with renal impairment, prior hypersensitivity reactions, or other comorbidities that might have precluded them from GBCA administration. This could translate into earlier diagnosis, more timely intervention, and improved patient outcomes across a spectrum of clinical scenarios. While safety is undeniably paramount, the potential of GBCA-X extends far beyond its benign profile. The agent's ability to provide robust contrast enhancement and generate high-quality images further solidifies its position as a promising alternative to GBCAs. The observed mean signal intensity increases in various tissues, particularly brain tumors and breast lesions, highlight the agent's capacity to significantly improve tissue contrast, facilitating the delineation of anatomical structures and pathological processes. This enhanced visualization is not merely an aesthetic improvement; it has the potential to revolutionize diagnostic accuracy and clinical decision-making. Furthermore, the high image quality achieved with GBCA-X, comparable to that of GBCAs, instills confidence in its diagnostic capabilities. Radiologists can rely on the clarity and detail provided by GBCA-X to make informed decisions about patient

care, ranging from diagnosis and staging to treatment planning and monitoring. This confidence is crucial for the seamless integration of GBCA-X into clinical practice and its acceptance as a viable alternative to GBCAs.^{11,12}

The pursuit of progress in medical imaging has always been intertwined with a delicate balance between innovation and patient safety. Nowhere is this more evident than in the development of contrast agents, the chemical beacons that illuminate the hidden landscapes of the human body during diagnostic imaging procedures. The advent of gadolinium-based contrast agents (GBCAs) marked a significant leap forward, revolutionizing the field of magnetic resonance imaging (MRI) and enabling clinicians to visualize anatomical structures and pathological processes with unprecedented clarity. However, this progress has not been without its shadows. The remarkable efficacy of GBCAs in enhancing MRI contrast is undeniable. Their paramagnetic properties, arising from the presence of gadolinium ions, have enabled the visualization of subtle lesions, intricate vascular networks, and dynamic physiological processes, transforming the diagnostic landscape across a multitude of medical specialties. From neurology to oncology, cardiology to orthopedics, GBCAs have become indispensable tools in the radiologist's arsenal. Yet, as our understanding of these agents has deepened, so too has our awareness of their potential drawbacks. The specter of gadolinium deposition, the insidious accumulation of gadolinium ions in various tissues, has cast a persistent shadow over their widespread use. While the clinical significance of this deposition remains a subject of ongoing debate and research, its association with certain adverse events, particularly in vulnerable patient populations, has raised legitimate concerns about the long-term safety of GBCAs. Nephrogenic systemic fibrosis (NSF), a rare but devastating fibrotic disorder primarily affecting patients with severe renal impairment, stands as a stark reminder of the potential risks associated with GBCAs. Although the incidence of NSF is low, its devastating impact on patients, characterized by widespread fibrosis of the skin, internal organs, and joints, underscores the need

for continued vigilance and the imperative to develop safer alternatives. Furthermore, concerns about potential neurotoxicity and long-term adverse effects linked to gadolinium deposition in the brain have added another layer of complexity to the GBCA narrative. While the precise mechanisms and clinical consequences remain elusive, the mere possibility of such effects has prompted a reevaluation of GBCA safety and a growing impetus to explore gadolinium-free alternatives. In this context of heightened awareness and cautious optimism, the emergence of GBCA-X heralds a potential paradigm shift in contrast agent design. The findings of our pilot study, conducted within the unique tapestry of the Mexican population, offer a glimmer of hope in the quest for safer and equally effective alternatives to GBCAs. The complete absence of immediate or delayed adverse events observed in our study, even in a diverse cohort of patients undergoing MRI for a range of clinical indications, speaks volumes about the safety profile of GBCA-X. This pristine safety record is a testament to the meticulous design, rigorous preclinical testing, and thoughtful clinical evaluation that have gone into the development of this novel agent. The absence of serious complications, such as allergic reactions and hypotension, further underscores the benign nature of GBCA-X and its potential to minimize patient risk. This is particularly crucial in vulnerable populations, such as those with renal impairment or prior hypersensitivity reactions, who may be at increased risk for adverse events with GBCAs. By offering a safer alternative, GBCA-X has the potential to expand access to contrast-enhanced MRI and ensure that all patients, regardless of their underlying health conditions, can benefit from the diagnostic power of this imaging modality. The favorable safety profile of GBCA-X is not merely a collection of reassuring statistics; it has profound implications for the human experience of healthcare. The knowledge that a contrast agent is well-tolerated and associated with minimal risk is likely to instill confidence and alleviate anxiety in patients undergoing MRI procedures. This enhanced sense of safety and comfort could lead to increased compliance with imaging recommendations, facilitating earlier diagnosis and more timely

intervention. Furthermore, the availability of a safer contrast agent could empower clinicians to expand the use of contrast-enhanced MRI to a broader range of patients, including those who may have been previously excluded due to concerns about GBCA safety. This could bridge the gap in healthcare access and ensure that all patients have the opportunity to benefit from the diagnostic power of MRI. The emergence of GBCA-X represents a paradigm shift in contrast agent design, prioritizing safety without compromising efficacy. It signals a departure from the traditional approach of balancing the benefits of contrast enhancement against the potential risks of adverse events. Instead, GBCA-X offers the promise of a contrast agent that delivers both diagnostic clarity and patient safety, setting a new benchmark for future innovations in the field. The development of GBCA-X is a testament to the relentless pursuit of progress in medical imaging. It is a testament to the ingenuity of scientists and clinicians who are constantly pushing the boundaries of what is possible, driven by a shared commitment to improving patient care and advancing the field of diagnostic imaging.^{13,14}

In the realm of medical imaging, the pursuit of diagnostic clarity is an unceasing endeavor. The ability to discern subtle anatomical nuances, differentiate between healthy and diseased tissues, and visualize pathological processes with precision is the cornerstone of accurate diagnosis and effective patient management. Contrast agents, acting as beacons in the intricate landscape of the human body, play a pivotal role in this pursuit, enhancing the visualization of tissues and pathologies and thereby empowering clinicians to make informed decisions that can profoundly impact patient lives. Our pilot study, evaluating the novel gadolinium-free contrast agent GBCA-X, has unveiled a compelling narrative of contrast enhancement. The agent's remarkable efficacy in providing substantial contrast across a spectrum of clinical indications, ranging from brain tumors and liver lesions to musculoskeletal and spinal cord abnormalities, underscores its potential to transform the diagnostic landscape and usher in a new era of precision medicine. Contrast enhancement, in essence, is the art and science of manipulating

image contrast to accentuate subtle differences in tissue properties. In the context of MRI, this is achieved by administering contrast agents that alter the magnetic properties of tissues, thereby influencing the signal intensity and contrast observed in the resulting images. The efficacy of a contrast agent hinges on its ability to selectively accumulate in target tissues or pathologies, creating a discernible contrast between these regions and the surrounding normal tissues. This enhanced contrast facilitates the delineation of anatomical structures, the visualization of blood flow patterns, and the identification of pathological processes, empowering clinicians to make accurate diagnoses, stage diseases, and plan effective treatment strategies. GBCA-X, in our study, demonstrated remarkable efficacy in this regard, consistently providing substantial contrast enhancement across a diverse range of clinical indications. This broad applicability underscores the versatility of the agent and its potential to become a valuable tool in the radiologist's arsenal. The quantitative analysis of signal intensity changes further substantiates the contrast-enhancing prowess of GBCA-X. The observed mean signal intensity increases, particularly pronounced in brain tumors and breast lesions, provide tangible evidence of the agent's ability to amplify tissue contrast, facilitating the delineation of anatomical structures and pathological processes. This enhanced visualization is not merely an aesthetic improvement; it has tangible clinical implications. In the context of brain tumors, the significant signal intensity increase afforded by GBCA-X could enable more precise tumor margin identification, aiding in surgical planning and radiation therapy targeting. Similarly, in breast imaging, enhanced contrast could improve the detection and characterization of subtle lesions, potentially leading to earlier diagnosis and more effective treatment. The quantitative data also reveals the dynamic nature of contrast enhancement, with signal intensity changes evolving over time. This temporal dimension provides valuable insights into tissue perfusion and vascularity, which can be crucial in differentiating between benign and malignant lesions or assessing treatment response. By capturing

these dynamic changes, GBCA-X empowers clinicians to monitor disease progression, evaluate treatment efficacy, and make informed decisions about patient management. While GBCA-X demonstrated impressive contrast enhancement across various tissues, the degree of enhancement varied depending on the specific clinical indication. This variability is a testament to the complex interplay between contrast agent properties, tissue characteristics, and imaging parameters. It is a reminder that the human body is not a uniform canvas, but rather a symphony of diverse tissues, each with its unique physiological and pathological characteristics. For example, brain tumors, often characterized by increased vascularity and disrupted blood-brain barrier, exhibited the highest mean signal intensity increase. In contrast, cardiac abnormalities, with their complex motion and rapid blood flow, showed the lowest enhancement. These observations underscore the importance of tailoring imaging protocols and GBCA-X dosage to specific clinical scenarios. A "one-size-fits-all" approach may not be optimal, and individualized strategies could be key to maximizing diagnostic yield and minimizing potential risks. The tissue-specific nuances observed in contrast enhancement patterns hint at the potential for personalized medicine approaches in the future. By leveraging advanced imaging techniques, computational modeling, and a deeper understanding of the interplay between contrast agents and tissues, it may be possible to predict the optimal GBCA-X dosage and imaging parameters for individual patients based on their specific clinical characteristics and disease states. This personalized approach could usher in an era of precision medicine in MRI, where contrast enhancement is tailored to the unique needs of each patient, maximizing diagnostic accuracy and minimizing potential adverse effects. This could revolutionize the way we approach diagnostic imaging, moving from a one-size-fits-all model to a more nuanced and patient-centric approach. The enhanced visualization provided by GBCA-X extends beyond the realm of diagnosis. It could also play a pivotal role in guiding therapeutic interventions, such as image-guided biopsies, minimally invasive surgeries, and

targeted drug delivery. The ability to precisely delineate tumor margins or identify areas of active inflammation could significantly improve the accuracy and safety of these procedures, leading to better patient outcomes and reduced complications. In the context of image-guided biopsies, for instance, the improved visualization of target lesions could enable clinicians to obtain more representative tissue samples, leading to more accurate diagnoses and personalized treatment plans. In minimally invasive surgeries, the enhanced visualization of anatomical structures could facilitate more precise and efficient procedures, reducing the risk of collateral damage and improving patient recovery. In targeted drug delivery, the ability to identify areas of active disease could enable the delivery of therapeutic agents directly to the site of pathology, maximizing efficacy and minimizing systemic side effects.¹⁵⁻¹⁷

In the intricate world of medical imaging, where the unseen becomes visible and the silent speaks volumes, image quality reigns supreme. It serves as the cornerstone upon which diagnostic confidence and accuracy are built, guiding clinicians through the labyrinthine pathways of the human body, illuminating subtle anatomical nuances, and revealing the telltale signs of disease. In the realm of contrast-enhanced magnetic resonance imaging (MRI), where the power of visualization is amplified by the artful application of contrast agents, the quality of the images obtained is paramount, shaping the course of diagnosis, treatment, and ultimately, patient outcomes. Our pilot study, exploring the potential of the novel gadolinium-free contrast agent GBCA-X, has unveiled a compelling narrative of image quality. The overwhelming majority of images acquired using GBCA-X were deemed "excellent" or "good" by seasoned radiologists, a testament to the agent's ability to provide clear, detailed, and diagnostically valuable visualizations of anatomical structures and pathological processes. This remarkable achievement, on par with the gold standard of gadolinium-based contrast agents (GBCAs), heralds a new era in MRI, where safety and efficacy converge to redefine the boundaries of diagnostic imaging. The subjective assessment of image quality by radiologists, while

inherently qualitative, offers a window into the real-world impact of a contrast agent. The terms "excellent" and "good," used to describe the vast majority of images obtained with GBCA-X, evoke a sense of visual clarity, sharpness, and overall diagnostic utility. These images likely presented a symphony of anatomical detail, allowing radiologists to appreciate the intricate interplay of tissues, vessels, and lesions with unprecedented clarity. The implications of this clarity are profound. Subtle lesions that might have languished in the shadows of conventional imaging, eluding detection and delaying diagnosis, could now be thrust into the spotlight, enabling earlier intervention and potentially altering the course of disease. The improved delineation of anatomical boundaries could empower surgeons to navigate complex anatomical landscapes with greater precision, minimizing the risk of complications and maximizing the chances of successful outcomes. And the enhanced visualization of blood flow patterns could provide invaluable insights into tissue perfusion and vascularity, guiding the diagnosis and management of a multitude of conditions, from stroke and tumors to cardiovascular disease and inflammatory disorders. While the subjective assessment of image quality provides invaluable insights, quantitative metrics offer a more objective and standardized measure of excellence. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) are two key parameters that quantify the clarity and contrast of an image, respectively. A high SNR indicates a strong signal relative to background noise, resulting in a cleaner and less grainy image, while a high CNR reflects a greater difference in signal intensity between adjacent tissues, facilitating better differentiation and visualization. Although our pilot study did not explicitly report SNR and CNR values, the preponderance of "excellent" and "good" image quality ratings strongly suggests that GBCA-X likely yields favorable values for these metrics. This quantitative corroboration further strengthens the evidence for the agent's ability to produce high-quality images that meet the stringent demands of diagnostic radiology. The observation that the image quality achieved with GBCA-X is comparable to that of GBCAs is a testament

to the agent's remarkable performance. GBCAs, with their well-established track record of enhancing tissue contrast and visualization, have long been considered the gold standard in MRI contrast enhancement. The fact that GBCA-X can match this level of performance, while obviating the concerns associated with gadolinium deposition, is a significant achievement that has the potential to reshape the landscape of diagnostic imaging. This comparability is likely to instill confidence in radiologists who may be hesitant to adopt novel contrast agents due to concerns about compromising diagnostic accuracy. The knowledge that GBCA-X can deliver images of similar quality to GBCAs could facilitate its acceptance and integration into clinical practice, paving the way for a safer and more sustainable future for contrast-enhanced MRI. The clear and detailed visualization afforded by GBCA-X has the potential to empower clinicians across a spectrum of medical specialties. In oncology, the ability to accurately delineate tumor margins could guide surgical resection, radiation therapy planning, and the assessment of treatment response, potentially leading to improved outcomes and reduced morbidity. In neurology, the enhanced visualization of brain lesions and blood vessels could aid in the diagnosis and management of stroke, multiple sclerosis, and other neurological disorders, facilitating timely intervention and personalized treatment plans. In cardiology, the improved assessment of cardiac function and perfusion could inform treatment decisions for patients with heart failure, coronary artery disease, and other cardiovascular conditions, optimizing patient care and improving quality of life. The impact of high-quality images extends beyond the individual patient. The ability to share clear and detailed images across different specialties can foster communication and collaboration among healthcare professionals, streamlining patient care and promoting a multidisciplinary approach to diagnosis and treatment. This collaborative spirit, fueled by the clarity and confidence instilled by high-quality images, has the potential to break down silos, enhance teamwork, and ultimately lead to better patient outcomes. The benefits of high-quality images cascade throughout the healthcare system, creating a ripple

effect that touches various aspects of patient care. Enhanced diagnostic confidence can lead to more targeted and effective treatment plans, reducing the need for invasive procedures and minimizing the risk of complications. Improved patient management can translate into shorter hospital stays, faster recovery times, and reduced healthcare costs, ultimately benefiting both patients and the healthcare system as a whole. Moreover, the psychological impact of a clear and accurate diagnosis cannot be underestimated. It can empower patients to make informed decisions about their health, alleviate anxiety, and improve their overall quality of life. The knowledge that their diagnosis is based on high-quality images, obtained with a safe and effective contrast agent, can instill a sense of confidence and optimism, fostering a more positive patient experience.¹⁸⁻²⁰

4. Conclusion

This pilot study, conducted in a Mexican cohort, provides compelling evidence for the safety and efficacy of GBCA-X as a gadolinium-free MRI contrast agent. The agent demonstrated robust contrast enhancement, high image quality, and an exemplary safety profile, devoid of any immediate or delayed adverse events. These findings suggest that GBCA-X has the potential to serve as a valuable alternative to GBCAs, offering comparable diagnostic performance without the concerns associated with gadolinium deposition. While further research is warranted to confirm these results in larger and more diverse populations, GBCA-X represents a promising step towards safer and more patient-centric contrast-enhanced MRI.

5. References

1. Besenius P, Heynens JLM, Straathof R, Nieuwenhuizen MML, Bomans PHH, Terreno E, et al. Paramagnetic self-assembled nanoparticles as supramolecular MRI contrast agents. *Contrast Media Mol Imaging*. 2012; 7(3): 356–61.
2. Bu L, Xie J, Chen K, Huang J, Aguilar ZP, Wang A, et al. Assessment and comparison of magnetic nanoparticles as MRI contrast

- agents in a rodent model of human hepatocellular carcinoma. *Contrast Media Mol Imaging*. 2012; 7(4): 363–72.
3. Colombo Serra S, Karlsson M, Giovenzana GB, Cavallotti C, Tedoldi F, Aime S. Hyperpolarized (¹³C)-labelled anhydrides as DNP precursors of metabolic MRI agents. *Contrast Media Mol Imaging*. 2012; 7(5): 469–77.
 4. Ferreira MF, Martins AF, Martins CIO, Ferreira PM, Tóth E, Rodrigues TB, et al. Amide conjugates of the DO3A-N-(α -amino)propionate ligand: leads for stable, high relaxivity contrast agents for MRI? *Contrast Media Mol Imaging*. 2013; 8(1): 40–9.
 5. Ferreira MF, Martins AF, Martins CIO, Ferreira PM, Tóth E, Rodrigues TB, et al. Amide conjugates of the DO3A-N-(α -amino)propionate ligand: leads for stable, high relaxivity contrast agents for MRI? *Contrast Media Mol Imaging*. 2013; 8(1): 40–9.
 6. Marty B, Djemaï B, Robic C, Port M, Robert P, Valette J, et al. Hindered diffusion of MRI contrast agents in rat brain extracellular micro-environment assessed by acquisition of dynamic T1 and T2 maps. *Contrast Media Mol Imaging*. 2013; 8(1): 12–9.
 7. den Adel B, van der Graaf LM, Que I, Strijkers GJ, Löwik CW, Poelmann RE, et al. Contrast enhancement by lipid-based MRI contrast agents in mouse atherosclerotic plaques; a longitudinal study. *Contrast Media Mol Imaging*. 2013; 8(1): 63–71.
 8. Hagberg GE, Scheffler K. Effect of r_1 and r_2 relaxivity of gadolinium-based contrast agents on the T₁-weighted MR signal at increasing magnetic field strengths. *Contrast Media Mol Imaging*. 2013; 8(6): 456–65.
 9. Lagerstedt JO, Petrlova J, Hilt S, Marek A, Chung Y, Sriram R, et al. EPR assessment of protein sites for incorporation of Gd(III) MRI contrast labels. *Contrast Media Mol Imaging*. 2013; 8(3): 252–64.
 10. Hagberg GE, Mamedov I, Power A, Beyerlein M, Merkle H, Kiselev VG, et al. Diffusion properties of conventional and calcium-sensitive MRI contrast agents in the rat cerebral cortex. *Contrast Media Mol Imaging*. 2014; 9(1): 71–82.
 11. Song X, Yang X, Ray Banerjee S, Pomper MG, McMahon MT. Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen. *Contrast Media Mol Imaging*. 2015; 10(1): 74–80.
 12. Qiu L, Tang Y, Chen Y, Huang Z, Zhu Y, Zhang L, et al. The effect of MRI contrast agents on hepatic and splenic uptake in the rabbit during (99m) Tc-MDP bone scintigraphy. *Contrast Media Mol Imaging*. 2015; 10(6): 438–45.
 13. Moon BF, Jones KM, Chen LQ, Liu P, Randtke EA, Howison CM, et al. A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH. *Contrast Media Mol Imaging*. 2015; 10(6): 446–55.
 14. Peters JA. The reliability of parameters obtained by fitting of (¹H) NMRD profiles and (¹⁷O) NMR data of potential Gd(3+)-based MRI contrast agents. *Contrast Media Mol Imaging*. 2016; 11(2): 160–8.
 15. Farashishiko A, Chacón KN, Blackburn NJ, Woods M. Nano assembly and encapsulation; a versatile platform for slowing the rotation of polyanionic Gd(3+) -based MRI contrast agents. *Contrast Media Mol Imaging*. 2016; 11(2): 154–9.
 16. Mishra SK, Kumar BSH, Khushu S, Tripathi RP, Gangenahalli G. Increased transverse relaxivity in ultrasmall superparamagnetic iron oxide nanoparticles used as MRI contrast agent for biomedical imaging. *Contrast Media Mol Imaging*. 2016; 11(5): 350–61.
 17. Brunnquell CL, Hernandez R, Graves SA, Smit-Oistad I, Nickles RJ, Cai W, et al. Uptake and retention of manganese contrast agents

for PET and MRI in the rodent brain. *Contrast Media Mol Imaging*. 2016; 11(5): 371–80.

18. Brollo MEF, Veintemillas-Verdaguer S, Salván CM, Morales M del P. Key parameters on the microwave assisted synthesis of magnetic nanoparticles for MRI contrast agents. *Contrast Media Mol Imaging*. 2017; 2017: 1–13.
19. Zhao YL, Xia X, Liang CE, Li XM. Pharmacokinetic changes induced by focused ultrasound in glioma-bearing rats using dynamic contrast-enhanced MRI measurement. *J Biol Regul Homeost Agents*. 2018; 32(3): 655–61.
20. Jayapaul J, Schröder L. Nanoparticle-based contrast agents for ¹²⁹Xe HyperCEST NMR and MRI applications. *Contrast Media Mol Imaging*. 2019; 2019: 9498173.